NextPoint Therapeutics
PrivateLast Round
Early Stage
VC
Jul 30, 2026
Total Funding Raised
$196M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
NextPoint Therapeutics is a biotechnology company developing precision immuno-oncology therapeutics that target the B7-H7/HHLA2 immune checkpoint axis to treat solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NextPoint Therapeutics Comparables
Compare NextPoint Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Harbour BioMed | 78% | |
| BeOne Medicines | 76% | |
| Hummingbird Bioscience | 71% |
NextPoint Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Stage VC | Jul 30, 2026 | ||||
| Series B Extension | Feb 14, 2024 | ||||
| Series B | Jan 10, 2023 | ||||
| Series A | Aug 13, 2020 |
Key People
Founding team and executive leadership
NextPoint Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM Capital | VC Round |
| Sixty Degree Capital | Series B Extension, Series B |
| Binney Street Capital | Series A, VC Round, Series B Extension, Series B |
| MPM BioImpact | Series B, Series A, Series B Extension |
| Catalio Capital Management | Series B, Series B Extension |
| Invus Opportunities | Series B Extension, Series B |
| Arkin Bio Capital | Series B Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 51% MoM.
- Jul 30, 2026
$34M raised in early stage VC round.
NextPoint Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about NextPoint Therapeutics's valuation, stock price, and market status.
Is NextPoint Therapeutics a public or private company?
NextPoint Therapeutics is a private company.
What is the current stock price of NextPoint Therapeutics?
NextPoint Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is NextPoint Therapeutics worth (valuation)?
Valuation information for NextPoint Therapeutics is not publicly available.
Can I buy NextPoint Therapeutics stock?
NextPoint Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was NextPoint Therapeutics's last funding round?
NextPoint Therapeutics's most recent funding round was Series B Extension on February 14, 2024.
Who are the main investors in NextPoint Therapeutics?
Key investors in NextPoint Therapeutics include MPM Capital, Catalio Capital Management, Sanofi Ventures, Leaps by Bayer.
Will NextPoint Therapeutics IPO soon?
No public IPO plans have been announced for NextPoint Therapeutics.
How can I track NextPoint Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NextPoint Therapeutics's secondary market activity and sign up for updates.